Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells
- PMID: 31097086
- DOI: 10.1016/j.lungcan.2019.04.023
Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells
Abstract
Objectives: Increased FGFR1 expression is associated with resistance to tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC cells and often concomitant with epithelial to mesenchymal transition (EMT). However, the cause-and-effect relationship between increased FGFR1 expression and EMT in the genetic background of EGFR-mutated non-small cell lung cancer (NSCLC) cells is not clear. Previous studies have specifically addressed the relationship between EMT and increased FGFR1 expression in the context of simultaneous TKI-mediated blocking of EGFR-signaling. Here, in the context of EGFR-mutated NSCLC cells with active EGFR-signaling, we have examined whether increased FGFR1 expression drives EMT or is an EMT passenger event.
Materials and methods: For cause-and-effect analyses between EMT and FGFR1 expression, including expression of alternative spliced FGFR1 isoforms, we used CRISPR-dCAS9-SAM-mediated induction of the endogenous FGFR1 and ZEB1 genes, as well as biochemical EMT-induction, in PC9 and HCC827 NSCLC cell lines harboring activating EGFR-mutations.
Results: We find that FGFR1 expression correlates with a ZEB1-associated EMT gene expression profile in NSCLC cells. In experiments using NSCLC cell lines harboring activating EGFR-mutations we show that CRISPR-dCAS9-SAM-mediated induction of FGFR1 expression is neither driving an increase in ZEB1 expression nor EMT characteristics. However, CRISPR-dCAS9-SAM-mediated induction of ZEB1 expression drives EMT characteristics and an increase in FGFR1 expression. Biochemical induction of EMT also drives an increase in FGFR1 expression.
Conclusion: From our findings concerning the cause-and-effect relationship in the genetic background of EGFR-mutated NSCLC cells, we conclude that an increase in ZEB1 expression is a driver of EMT resulting in concomitant increased FGFR1 expression, whereas an increase in FGFR1 expression is insufficient to drive concomitant EMT.
Keywords: CRISPR-dCAS9; EGFR; EMT; FGFR1; NSCLC; ZEB1.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.J Thorac Oncol. 2016 Jul;11(7):1051-63. doi: 10.1016/j.jtho.2016.03.006. Epub 2016 Mar 19. J Thorac Oncol. 2016. PMID: 27006151
-
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.Oncogene. 2019 Sep;38(37):6399-6413. doi: 10.1038/s41388-019-0887-2. Epub 2019 Jul 19. Oncogene. 2019. PMID: 31324888 Free PMC article.
-
Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.Thorac Cancer. 2020 Jul;11(7):1934-1943. doi: 10.1111/1759-7714.13485. Epub 2020 May 20. Thorac Cancer. 2020. PMID: 32433828 Free PMC article.
-
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer.Biol Rev Camb Philos Soc. 2018 Nov;93(4):1735-1746. doi: 10.1111/brv.12416. Epub 2018 Apr 19. Biol Rev Camb Philos Soc. 2018. PMID: 29671943 Review.
-
[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer].Zhongguo Fei Ai Za Zhi. 2018 Dec 20;21(12):907-911. doi: 10.3779/j.issn.1009-3419.2018.12.08. Zhongguo Fei Ai Za Zhi. 2018. PMID: 30591098 Free PMC article. Review. Chinese.
Cited by
-
Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells.Transl Lung Cancer Res. 2020 Oct;9(5):1904-1914. doi: 10.21037/tlcr-20-522. Transl Lung Cancer Res. 2020. PMID: 33209611 Free PMC article.
-
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.Pharmgenomics Pers Med. 2021 Mar 9;14:301-317. doi: 10.2147/PGPM.S242045. eCollection 2021. Pharmgenomics Pers Med. 2021. PMID: 33727854 Free PMC article. Review.
-
Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-mediated gene-disruptions corroborate the MIR141/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT-associated EGFR TKI-resistance in NSCLC cells.Transl Lung Cancer Res. 2023 Jan 31;12(1):42-65. doi: 10.21037/tlcr-22-507. Epub 2023 Jan 13. Transl Lung Cancer Res. 2023. PMID: 36762066 Free PMC article.
-
Nanomedicines for Overcoming Cancer Drug Resistance.Pharmaceutics. 2022 Aug 1;14(8):1606. doi: 10.3390/pharmaceutics14081606. Pharmaceutics. 2022. PMID: 36015232 Free PMC article. Review.
-
CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries.Cancer Gene Ther. 2021 Jun;28(6):566-580. doi: 10.1038/s41417-020-00256-7. Epub 2020 Nov 15. Cancer Gene Ther. 2021. PMID: 33191402 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous